echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Inventory of listing, financing and mergers and acquisitions in the biomedical field in 2019

    Inventory of listing, financing and mergers and acquisitions in the biomedical field in 2019

    • Last Update: 2020-01-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    By Wang Haitao ·In 2019, 43 biopharmaceutical companies were listed, raising 36.24 billion yuan; ·In 2019, there were 857 financing events in China's biomedical field, with a total financing amount of RMB 111.56 billion The financing rounds were mainly in round a, and the cities were mainly in Beijing, Shanghai and Hangzhou; ·In 2019, there were 609 M & A events in China's biomedical sector, with a total financing amount of 109.548 billion yuan, and the main board's M & a performance was the most active According to the database of Huoshi creation, in 2019, 43 companies in the field of biomedicine were listed, raising a total of 36.24 billion yuan There are 15 listed on Shanghai Stock Exchange (14 on science and technology innovation board, 1 on main board), 3 on Shenzhen Stock Exchange (2 on growth enterprise board, 1 on small and medium-sized board), 11 on behalf of transfer market, 12 on Hong Kong stock exchange, and 2 on Nasdaq Stock Exchange Among them, KANGLONG Huacheng was listed on the growth enterprise market of Shenzhen Stock Exchange and Hong Kong Stock Exchange on January 28, 2019 and November 28, 2019, respectively It is the only bio pharmaceutical enterprise that has achieved multi listing in 2019 The initial public offering of Shanghai Stock Exchange actually raised 11.835 billion yuan, Shenzhen Stock Exchange 1.758 billion yuan, Hong Kong Stock Exchange 21.452 billion yuan, and Nasdaq Stock Exchange 598 million yuan See Table 1 Data source: flint creation database By the end of 2019, a total of 874 biopharmaceuticals had been listed on the market, raising 252.09 billion yuan Among them, there are 197 Shenzhen stock exchanges (38 main boards, 84 growth enterprises and 75 small and medium-sized boards), raising 97.58 billion yuan According to the Huoshi creation database, 117 Shanghai stock exchanges (14 science and technology innovation boards and 103 mainboards) have raised 51.78 billion yuan, 504 stock exchanges have been listed, 58 Hong Kong stock exchanges have been listed, and 99.31 billion yuan has been raised The total number of the three major exchanges in the United States is 11, with 3.43 billion yuan in total Figure 1 listing quantity and financing of national biomedicine in each exchange market (Note: the exchange rate is converted by listing on the same day) According to Huoshi creation database, in 2019, there were 857 financing events in China's biomedical field, with a total financing amount of RMB 111.56 billion; the financing rounds were mainly in round a; the cities were mainly in Beijing, Shanghai and Hangzhou In 2019, the biomedical field mainly focused on round a financing, with a total of 308 cases, with a financing amount of 26.27 billion yuan; followed by strategic financing, with a total of 166 cases, with a financing amount of 48.47 billion yuan; Figure 2 financing rounds and amount of bio pharmaceutical enterprises in 2019 In 2019, financing events are mainly concentrated in Beijing, Shanghai and Hangzhou, with 192, 179 and 65 events respectively In terms of financing amount, although Nantong and Changchun have financing amount of 6 and 2 respectively, the financing amount has reached 7.56 billion yuan and 5.637 billion yuan respectively, ranking third and fourth in the city Figure 3 distribution of some cities in 2019 financing of biomedical Enterprises Note: the strategic financing stage will be eliminated in 2019 According to Huoshi creation database, there are 609 M & A events in China's biomedical field in 2019, with a total financing amount of 109.548 billion yuan, and the main board's M & a performance is the most active In 2019, there were 609 M & A events involving 109.548 billion yuan in China's biomedical field, including 366 ongoing M & A events involving 52.839 billion yuan, 230 completed M & A events involving 54.861 billion yuan, 13 failed M & A events involving 1.848 billion yuan Figure 4 progress of biopharmaceutical M & A in 2019 After eliminating the failure events, from the perspective of the board, at present, the main board M & A events are the most active in both the number of M & A and the amount involved In the whole year, the main board involved 205 M & A events, involving a total amount of 64 billion 63 million yuan; although the number of M & A events in the new third board was 195, the capital involved was only 2 billion 719 million yuan; there were 118 M & A events in the growth enterprise board, involving a capital of 16 billion 219 million yuan; there were 78 M & A events in the small and medium-sized board, involving a total amount of 24 billion 999 million yuan Figure 5 distribution of biomedical M & a listed sectors in 2019 In the field of chemical pharmacy, M & A is the most active, with 148 M & A events involving 28.247 billion yuan; in the field of medical devices, although M & A events are frequent, the amount involved is the least, with 7.741 billion yuan; in the field of traditional Chinese Medicine II, there are 98 M & A events involving 13.553 billion yuan Figure 6 distribution of biomedical M & A in 2019 See Table 3 for the top 10 enterprises involved in M & A in the field of biomedicine in 2019.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.